1. Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity
   Alina V. Meyer et al, 2020, Frontiers in Oncology CrossRef
2. CD73 and PD-L1 as Potential Therapeutic Targets in Gallbladder Cancer
   Lu Cao et al, 2022, International Journal of Molecular Sciences CrossRef
3. The exploitation of enzyme-based cancer immunotherapy
   Gourav Chandan et al, 2022, Human Cell CrossRef
4. The CD73 immune checkpoint promotes tumor cell metabolic fitness
   David Allard et al, 2023, eLife CrossRef
5. Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?
   Tiziana Vaisitti et al, 2018, International Journal of Molecular Sciences CrossRef
6. What Else Can CD39 Tell Us?
   Hai Zhao et al, 2017, Frontiers in Immunology CrossRef
7. Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
   Elisa Agostinetto et al, 2021, Current Oncology Reports CrossRef
8. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives
   Paola de Andrade Mello et al, 2017, Frontiers in Immunology CrossRef
9. Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
   Aitziber Buqué et al, 2016, OncoImmunology CrossRef
10. α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors
    Sanjay Bhattarai et al, 2015, Journal of Medicinal Chemistry CrossRef
11. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E
    Theresa Kordaß et al, 2018, Frontiers in Immunology CrossRef